Abstracts tagged "Disease Activity"

Abstract Number: 1537 • 2019 ACR/ARP Annual Meeting
Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
Stefan Siebert¹, Elisa Gremese ², Paul Bergmans ³, Kurt De Vlam ⁴, Beatriz Joven-Ibáñez ⁵, Gkikas Katsifis ⁶, Tatiana Korotaeva ⁷, Wim Noël ⁸, Carlo Selmi ⁹, Petros Sfikakis ¹⁰, Pavel Smirnov ¹¹, Elke Theander ¹², Michael Nurmohamed ¹³, Laure Gossec ¹⁴ and Josef Smolen ¹⁵, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ⁹Humanitas Research Hospital, University of Milan, Milan, Italy, ¹⁰Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹¹Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹²Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹³Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹⁴Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: The additional benefit of methotrexate as a concomitant treatment in PsA has not been fully elucidated. Observational data exist for concomitant methotrexate (MTX) use…
Abstract Number: 502 • 2019 ACR/ARP Annual Meeting
Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis
Mohammad Movahedi ¹, Deborah Weber ¹, Pooneh Akhavan ² and Edward Keystone³, ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Progressive rheumatoid arthritis (RA) is responsible for disabilities in this patient population, characterized by radiographic joint damage. Achieving low disease activity (LDA) in RA…
Abstract Number: 1559 • 2019 ACR/ARP Annual Meeting
Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE
Eric Morand¹, Kevin Zhang ¹, Sarah Boyd ¹, Francois Petitjean ¹, Alberta Hoi ², Rachel Koelmeyer ¹ and Hieu Nim ¹, ¹Monash University, Melbourne, Victoria, Australia, ²School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity…
Abstract Number: 564 • 2019 ACR/ARP Annual Meeting
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis
Jae-Bum Jun¹, Bon San Koo ², Seunghun Lee ³, Jinju Kim ⁴, Juyeon Kang ¹ and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ³Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Novartis Korea Ltd., Seoul
Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…
Abstract Number: 1615 • 2019 ACR/ARP Annual Meeting
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Yoshiyuki Arinuma ¹, Yasuhiro Hasegawa ¹, Takumi Muramatsu¹, Yu Matsueda ¹ and Kunihiro Yamaoka ¹, ¹Department of Rheumatology and Infectious Diseaes, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Background/Purpose: Autoantibodies against N-methyl-D-aspartate receptor subunit GluN2 (anti-GluN2) in the cerebrospinal fluid are known to be related with the development of diffuse psychiatric/neuropsychological manifestations in…
Abstract Number: 679 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Manifestations of SLE
Amanda Eudy¹, Jennifer Rogers ¹, Raeann Whitney ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Rebecca Sadun ¹, Kai Sun ¹ and Megan Clowse ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: Our group has developed a conceptual model to categorize SLE manifestations into two dimensions termed Type 1 and Type 2. Type 1 SLE consists…
Abstract Number: 1725 • 2019 ACR/ARP Annual Meeting
Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Emily Smitherman¹, Mary Beth Son ², Andrea Knight ³, Timothy Beukelman ⁴, Jeffrey Curtis ¹ and Aimee Hersh ⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of Utah, Salt Lake City, UT
Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE) despite widespread use of immunosuppressive therapy. There are…
Abstract Number: 321 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis All Disease Activities Are Not Created Equal
Keith Knapp¹ and Gary Craig², ¹Discus Analytics LLC, Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: Multiple composite RA disease activity (DA) metrics are approved for use; each reflect different aspects of disease. Many use similar measurements but their values…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…
Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Filip van Den Bosch¹, Siegfried Wassenberg², Boulos Haraoui³, Patrick Zueger⁴, Meijing Wu⁴, Ivan Lagunes Galindo⁴ and Andrew Ostor⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumazentrum Ratingen, Ratingen, Germany, ³Université de Montréal, Montreal, QC, Canada, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Melbourne, Australia
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
Abstract Number: 1840 • 2018 ACR/ARHP Annual Meeting
Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries’ Socioeconomics: Results from the Meteor Registry
Sytske Anne Bergstra¹, José Tavares Costa², David Vega-Morales³, Karen Salomon-Escoto⁴, Nimmisha Govind⁵, Cornelia F. Allaart¹ and Robert B.M. Landewé⁶, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology, University Hospital “Dr. José Eleuterio González”, UANL, Monterrey, Mexico, ⁴University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁵University of the Witwatersrand, Johannesburg, South Africa, ⁶Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: The treatment and prognosis of rheumatoid arthritis (RA) patients have improved tremendously, but patients across the world may not benefit similarly. One of the…
Abstract Number: 2457 • 2018 ACR/ARHP Annual Meeting
Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis
Britney Jones¹, Imran Hassan², Walter P. Maksymowych³ and Elaine Yacyshyn⁴, ¹University of Alberta, Edmonton, AB, Canada, ²EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ³CaRE Arthritis, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Inflammatory arthritis (IA) is a chronic disorder that encompasses rheumatoid and psoriatic arthritis. Rheumatoid cachexia is defined as elevated HDL, increased adiposity, and loss…
Abstract Number: 2643 • 2018 ACR/ARHP Annual Meeting
Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
Zahi Touma¹, Murray Urowitz², Dafna D Gladman², Carrie Wagner³, Bei Zhou³, Robert Gordon³, Benjamin Hsu³, Marc Chevrier³ and Shawn Rose³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of the cytokines IL-12 & IL-23, is being investigated in patients (pts) w/…
Abstract Number: 2951 • 2018 ACR/ARHP Annual Meeting
Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
Jarrat Jordan¹, Kristen Sweet², Matteo Cesaroni¹, Keying Ma², Carol Franks², Loqmane Seridi², Jessica Schreiter³, Robert Gordon², Peter E. Lipsky⁴, Shawn Rose², Frédéric Baribaud², Matthew Loza² and Kim Campbell², ¹Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: We previously reported that treatment with ustekinumab (UST), an anti-IL-12/23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of disease activity in a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].